This article was originally published here

Thorac Cancer. 2020 Jul 16. doi: 10.1111/1759-7714.13564. Online ahead of print.

ABSTRACT

BACKGROUND: Visceral pleural invasion (PVI) in adenocarcinoma of the lung is considered a poor prognostic factor. The purpose of this study was to analyze nucleolin and nucleophosmin expression in pulmonary adenocarcinoma (PA) with VPI and in pleural malignant mesothelioma.

METHODS: The study was conducted on the basis of 19 pathologically-confirmed cases of adenocarcinoma of the lung and 29 cases of epithelioid malignant mesothelioma. The nucleolin and nucleophosmin expression was assessed immunohistochemically and analyzed with image analysis software.

RESULTS: Nucleolin expression was lower while nucleophosmin was higher in pleural invasion of pulmonary adenocarcinoma than in the central part of the tumor. Differences in subpopulations of cells with different expression of proteins studied were also found. Malignant mesothelioma showed lower nucleolin expression than adenocarcinoma of the lung but no differences in nucleophosmin expression were found.

CONCLUSIONS: The results of our study suggested that lower nucleolin and higher nucleophosmin expression may be related to higher invasiveness of adenocarcinoma of the lung. Differences in nucleolin expression between pulmonary adenocarcinoma and malignant mesothelioma indicate another aspect of biology of these pleura-invading cancers that requires further study.

KEY POINTS: SIGNIFICANT FINDINGS OF THE STUDY: Differences in nucleolin and nucleophosmin expression in pleura invading pulmonary adenocarcinoma indicate the involvement of these proteins in its locoregional spread while differences in nucleolin expression between pulmonary adenocarcinoma and malignant mesothelioma suggest another aspect of biology of these cancers.

WHAT THIS STUDY ADDS: This is the first study on nucleolin and nucleophosmin expression in pleural malignant mesothelioma and pleura-invading pulmonary adenocarcinoma. Our findings may assist in understanding the mechanisms of locoregional spread of adenocarcinoma and differences between these two pleura-invading cancers.

PMID:32671956 | DOI:10.1111/1759-7714.13564

Here is the original post:

Nucleolin and nucleophosmin expression patterns in pulmonary adenocarcinoma invading the pleura and in pleural malignant mesothelioma - DocWire News

It IS a devastating diagnosis to be told that the reason you are now going to die is for simply doing your job.

That is the reality for hundreds of men and women in Wales. Decades after they were exposed to asbestos, which in some cases they were unaware of, it is now having deadly consequences.

Exposure to asbestos can result in a form of cancer called mesothelioma that causes shortness of breath, chest pain, cough and of which there is no cure.

Few of those diagnosed with mesothelioma survive more than 12 months after symptoms begin to show. It's a devastating and shocking blow to them and their families.

Many of those diagnosed in Wales are ex-miners, construction workers or those who worked in other industrial occupations in the 1960's and 1970's, when 170,000 tonnes of asbestos was imported to the UK each year.

Every year the number of people diagnosed with mesothelioma continues to grow as the consequences of working or coming into contact with asbestos 50 or 60 years ago come to fruition.

The latest figures show that between 2016 and 2018, 263 people in Wales were told they had the disease.

In many cases, otherwise fit, healthy and active people are suddenly facing a terminal cancer diagnosis decades after being exposed to the building material that caused their illness.

The dangers of working with asbestos were first documented in the early 1900's but it wouldn't be until 1999 that the potentially deadly material was made illegal in the UK.

Many industrial workers worked day-in day-out with asbestos, breathing in the deadly fibres from the material that would cause the onset of mesothelioma decades later.

The greater exposure to asbestos, the greater the risk of developing mesothelioma. Even washing the clothes of someone who worked with asbestos can be dangerous enough and lead to the disease taking root.

According to figures from the Health and Safety Executive in 2017, 2,087 men and 439 women died from mesothelioma in the UK.

The family of Roy Clift, from Duffryn Rhondda, believed he was exposed to asbestos while working for the National Coal Board and Ford Motor Company over six decades.

While working for the National Coal Board, between 1945 and 1966, Roy worked at Nantewlaith, Duffryn Rhondda and Caerau collieries as a fitter. Its alleged that Roy was required to work on asbestos brake pads on diesel locomotives and remove pipe work which was clad with asbestos.

Between 1966 and 1991, he worked at the large Ford site in Swansea. During this time, its believed that Roy regularly came into contact with asbestos-lagged pipe work.

Roy died of mesothelioma in 2016, just weeks after he began to show symptoms.

Law firm Hugh James helped Roys family secure a six-figure settlement from the National Coal Board and Ford Motor Company in May.

His wife Sadie Clift said: "It was a complete and utter shock. We realised Roy had worked with asbestos in the past, but didnt realise how dangerous it was.

"He became short of breath and, within a matter of weeks, his condition deteriorated rapidly and he passed away before we really had time to come to terms with it."

Sadie and Roy's grandson, who preferred not to be named, remembered his grandfather being "full of life and a happy, jolly man", until weeks before he died at the age of 86.

"Grandad would always be singing. He loved music and he'd have the whole family around. He'd be on the piano and my uncle on guitar, we'd get together for a bit of a drink.

"He worked hard all his life and all the hours that god sent. He was a very fit, big strong man and full of life up to five weeks before he died. The cancer came over him all of a sudden and it just went downhill rapidly.

"He got diagnosed with pneumonia at first but one night he came downstairs and said 'I can't breathe'. He was in hospital for a couple of weeks and was only diagnosed [with mesothelioma] three days before he died."

Roy was told by medical staff at the hospital that he had an industrial illness and he started legal action in the days before his death.

"It's heart-breaking to be honest. The compensation wont bring Roy back, but it will make my life a little easier," Sadie said.

As well as those families who are grieving, there are also those who are coming to terms with the shock of a mesothelioma diagnosis.

Wayne Phillips, 70, from Aberdare, has undergone years of chemotherapy and immunotherapy for terminal mesothelioma.

He made a successful compensation claim against his former employer, the construction firm George Wimpey, through Hugh James solicitors after he claimed he had been exposed to asbestos when working as an apprentice carpenter on building sites in the 1960's.

"At that time, asbestos was the saviour, it was everything. It was even used in ironing boards but I was using it in sheets for roofing," Wayne said.

"I was exposed to it for five or six years, but not constantly. The danger wasn't known at the time from what I can remember. I wasn't offered a mask, nothing.

"I'd be breaking up bits of asbestos and they'd fall on me and I'd breathe it in," Wayne said.

Four years ago, Wayne started to experience pain under his arm and across his chest. At first, he thought it might have been a pulled muscle from working out at the gym.

"It took a while to diagnose it. I saw an article in the newspaper about a nurse helping someone who thought they had a damaged rib and saying they had been suffering with pain for a long time. They found out what it was and said there was nothing they could do about it. I wrote the name down of what it was, took it to the doctor and said 'this is what I've got,'" Wayne said.

He said the diagnosis had come as "quite a shock" to him and his wife Patricia. Wayne said he had never smoked and rarely drank alcohol and exercised regularly at the gym.

"It's terminal so I'm having radiotherapy now. It won't do much to the cancer but it helps a bit with the pain.

"It absolutely changed our life overnight. We used to travel all over the world, but I've been unable to go on holiday because I can't get insurance."

Wayne was awarded a settlement from his previous employer.

"The money is handy but we cant really spend it because of my situation at the moment. Weve got an allotment but I cant dig really. I'm finding it hard to exert myself and I cant walk very far," he said.

Ken Dymond, 78, from Pembroke Dock, claims that he worked with asbestos in refineries and ships in Pembrokshire.

He is purusing legal action against a number of his former employers after being diagnosed with mesothelioma in February 2020.

His daughter Joanne Wiseman spoke about the family's shock at her dad's diagnosis.

"I'd never heard of it [mesothelioma] to be honest. I had to get someone to translate it for me so I could pronounce it properly.

"When you learn those words, you just wish you'd never heard them.

"It was a real shock. He had symptoms before not being able to breathe properly. He was lethargic and lost weight."

Ken was able to get his diagnosis with the help of Sarah Morgan from charity Mesothelioma UK and another charity Asbestos Awareness & Support Cymru [AASC].

Joanne said: "Jo [from AASC] pointed me in the right direction. We had no idea we could claim compensation.

"The life expectancy isn't very long and I would like people like my dad to have compensation while theyre alive and healthy.

"Realistically these people are often waiting too long for compensation. My dad paid with his life for going to work - thats the hardest thing to cope with."

The threat of asbestos didn't disappear with the 1999 ban. Homes, schools and other buildings constructed before 1985, when a partial ban on some type of asbestos came into force, may well contain asbestos as insulation.

Having asbestos in your home or school is not dangerous until the material is disturbed and specialist contractors can be called in to remove it safely.

Sadly though, for the thousands of men and women who were exposed to asbestos, the acknowledgement of its deadly effects has come too little, too late.

Action Mesothelioma Day was recently held on July 3. To find out more about mesothelioma and the charities that help those affected by it, see Mesothelioma UK or AASC.

More here:

How asbestos is continuing to destroy families more than 20 years after it was banned - Wales Online

The global COVID-19 pandemic has altered nearly every aspect of our daily lives. Unfortunately, the people facing a majority of these obstacles are patients with cancer and other chronic medical conditions such as mesothelioma.

Cancer patients know the difficulties associated with multiple doctor visits, unpredictable test results, chemotherapy or radiation side effects and daily emotional stress. The pandemic and rising case numbers have exacerbated these difficulties and challenged the basics of cancer patient care, including mesothelioma treatment.

These challenges have forced my practice and others to look for ways to improve the existing doctor-patient dynamic. One of the ways weve innovated to create something better than what existed before is our virtual multidisciplinary clinic for cancer patients at Sylvester Comprehensive Cancer Center.

Patients can be at home with as many family members as they want in a very comfortable environment. At the same time, they can see and talk with our entire interdisciplinary team as we develop a treatment plan tailored to them. Mesothelioma and other cancer patients get the benefit of expert-level care in a way that hasnt existed before.

When faced with a population of patients who rely on expert medical care regularly, how else can we meet these challenges and transform the status quo into something better for everyone?

I believe that change starts with long-needed improvements to doctor-patient communication.

Many clinicians receive training on how to communicate the implications of severe disease with patients in a way that limits fear, confusion and apprehension.

In the last few months, my colleagues and I have undergone additional training for maintaining that expert level of communication during virtual visits. Doctors should be able to deliver the same level of sensitivity and thoughtfulness in our discussions during eHealth visits as we do in person.

Its more important than ever to provide this level of care to our patients during a time when feelings of sadness and anxiety are prevalent.

In my practice, I have found that the best way to open dialogue with a patient is first to identify and deal with their emotions. Without acknowledging these stressful feelings right away, patients will struggle to absorb essential information about their illness and treatment.

During this time, patients are more likely to retain details regarding their care when physicians deliver the information in small doses. Patients should also feel empowered to disclose their wishes during a visit, which can be more challenging to discuss outside of an exam room.

When patients feel validated and understood, medical care becomes much more personal and practical.

Physicians who can adapt to todays changing standards and deliver this level of communication during a time of crisis will strengthen their listening and empathizing skills. This renewed focus benefits patients substantially and allows them to place their trust in cancer and mesothelioma specialists who have achieved new levels of wisdom and kindness.

Clinicians are dealing with heightened exhaustion and distress during the COVID-19 pandemic, but improved communication helps fight the challenges patients are experiencing in these trying times.

With constant news of the pandemic coming from an unlimited number of sources, physicians have a responsibility to provide accurate information as it becomes available. The impact of this is twofold: Patients get precise and factual updates, and doctors maintain an open line of communication with their patients.

Before the COVID-19 pandemic, the discourse between patients and physicians centered mostly around treatment plans and disease prognosis. Now, that relationship has the opportunity to expand into regular discussions that can ease patients fears about the pandemic and encourage them to reach out to their health care team more often.

Patients should feel empowered to contact providers they trust and ask questions about face coverings, medications, vaccines, social distancing and other concerns. Some patients may feel cautious about bothering their health care team during this time when they may be overwhelmed with a higher patient load.

I have encouraged all of my patients to reach out regularly. A side effect of this pandemic is the rampant spread of misinformation. Patients have a right to be armed with accurate and timely knowledge, and theres no better source than the health care team they already trust.

Since March 2020, ambulatory and outpatient visits for routine medical care have declined by as much as 40% in some areas.

Source: Commonwealth Fund, June 2020

The change in some practices, such as closed waiting rooms and the rise of telemedicine and eHealth, should not deter patients from seeking open communication with their doctor.

My team and I have made an effort to make the message clear: Health care may look different now, but its an opportunity to raise the quality of our practice and make medicine better.

With our virtual multidisciplinary clinic, multiple health care providers from different medical specialties, such as psychology and nutrition, participate during a single encounter. They bring all their expertise together to deliver a collective message, instead of the more traditional model of multiple separate meetings with different care providers.

This approach saves patients time and avoids parking, traffic and other common hassles of multiple visits. In more traditional cases, providers may not have communicated with each other efficiently, leading to confusing messages for patients about their treatment plans.

The virtual multidisciplinary clinic makes it easier to coordinate visits with multiple providers in different locations.

Patients should feel comfortable in the knowledge that physicians arent just dealing with the challenges of COVID-19; were adapting to them. And when everyone is back together, health care will be better than ever.

Free Mesothelioma GuideGet Answers to All Your Mesothelioma Questions

See the rest here:

COVID-19 and the Doctor-Patient Relationship - Asbestos.com

It turns out it did not. A new study, by John Boice, Jr. and colleagues, reports the results of 114,270 nuclear weapons test participants that were followed for up to 65 years. Contrary to decades of anecdotal reports, the study concluded that there were no statistically significant occurrence of cancers or adverse health effects from radiation among these soldiers.

OperationBuster-Jangle -Dogatomic bomb test at theNevada Test Site, had troops participating in ... [+] the exerciseDesert Rock I. It had a yield of 21 kilotons of TNT, and was the first U.S. nuclear field exercise conducted with live troops maneuvering on the ground. Troops were six miles from the blast. November 1, 1951.

Significant health effects of mesothelioma from asbestos, as well as berylliosis from beryllium, were observed, as was the case for many Cold War sites that routinely used these materials. But not from radiation

Approximately 235,000 military personnel participated at one of the 230 above-ground nuclear weapons tests in the United States from 1945 through 1962. At the Nevada Test Site, these soldiers participated in military maneuvers, observed nuclear weapons tests, or provided technical support (see figures). At the Pacific Proving Ground they served aboard ships or were stationed on islands during or after nuclear weapons tests.

The conclusion of the study was that no statistically significant radiation associations were observed among these 114,270 nuclear weapons test participants that were followed for up to 65 years.

While many weapons workers, soldiers and people have been monetarily compensated for being at, or downwind of, these sites, the cancer rates of these groups, populations and workers are no higher than the general population and, in many cases, are lower. There is no evidence their cancers came from radiation, and lots of evidence that they did not.

I dont at all mind giving sick people money, but I do mind pretending it has to do with low levels of radiation.

We have seen similar results from the Japanese survivors of the atomic bomb blasts in 1945. The explosion of atom bombs over the cities of Hiroshima and Nagasaki in August 1945 resulted in very high casualties from the blast but left a large number of survivors who had been exposed to radiation at the moment of the blast, at levels that could be reasonably ascertained. Extensive follow-up of a large cohort of survivors (120,000) and of their offspring (77,000) was initiated in 1947 and continues to this day.

Survivors that received huge whole body doses of 1 Gy irradiation (~1000 mSV, ~100 rem) have a significantly elevated rate of cancer (42% increase) but only limited decrease of longevity (about 1 year), while their offspring show no increased frequency of abnormalities and no detectable elevation in mutation rates.

Yet the general public, and indeed most scientists, are unaware of this, and widely believe that irradiated survivors suffered a very high cancer burdens and dramatically shortened life spans, and that their progeny were affected by elevated mutation rates and frequent abnormalities.

This misperception has led to dramatic fears of even low levels of radiation and fears of necessary medical radiological procedures. In other words, people have died because of this unfounded fear of radiation.

In addition, the often-hyped dead zones following nuclear blasts in futuristic scenarios also never materialized, even in Hiroshima and Nagasaki. These cities were rebuilt completely and had no radioactive legacy, and no increased incidences of cancer outside of those exposed at the actual moment of the atomic blast in 1945.

St George Utah, the site of the most downwind deposition of fallout from the Nevada Nuclear Test Site, has the second lowest cancer rates in the country. They also had no increased cancers from radiation.

It is very difficult, and very rare, for anyone to be hurt by any dose of radiation obtainable in our society, even working at nuclear sites.

Above-ground atomic bomb test at the Nevada Test Site while troops look on.

Not that we havent messed up in some ways. TheCastle Bravo testin the Pacific was probably the largest generator of fallout in history as it was detonated too close to the ground and the yield was larger than anyone expected.

At 15 megatons, that hydrogen bomb was the largest detonation ever by the United States and was one of the events that led to banning above-ground nuclear tests precisely because of that fallout and its horrible effect on the people of the Marshall Islands.

But that was a rare event.

Contrary to the hype of Fukushima, and even Chernobyl, the observable radiation health effects from both accidents were small. In the case of Fukushima, it was as close to zero as one can get. In the case of Chernobyl, it was still very small.

The reason you might not know this, is that almost everyone uses the wrong model to predict health effects from radiation at these levels, and anyone who gets cancer, which is common in every society, then attributes it to any nuclear or radiation event they can.

Only recently have the global health, nuclear and radiation agencies realized that error and are moving to correct. However, as with most scientists, this change has been quiet and sort of cloaked in scientific jargon. Its also very political since it involves a lot of money and has spanned a lot of time.

But the implications are enormous.

The latest scientific society to make clear that we have been doing this wrong is probably the most qualified to understand this issue the Health Physics Society. The Health Physics Society is the scientific body that includes radiation protection scientists. And they put out a position statement on Radiation Risk In Perspective, in which they advise against estimating health risks to people from exposures to ionizing radiation that are anywhere near natural background levels because statistical uncertainties at these low levels are great.

In other words, any possible adverse health effects resulting from radiation doses below 10,000 mrem (100 mSv) will not be detectable.

Background radiation across the Earth varies from 3 mrem/yr (0.03 mSv/yr) over the oceans to 10,000 mrem/yr (100 mSv/yr) in areas of high elevation made up of granitic rocks. Thus, it is not surprising that populations subjected to radiation levels of 10,000 mrem (100 mSv) or below, either natural or man-made, show radiation effects that are not statistically different from zero.

The reason that we refer to it as not statistically different from zero is that other normal causes of these health effects, particularly cancer, are thousands of times more common and more effective than radiation at producing cancers of all types, so there can never be a population with zero cancers.

As an example, in a general population of 100,000 people in the United States, about 40,000 1,600 people will naturally develop cancer over their lives with no help from radiation. If you subject this same population to radiation levels ten times their normal radiation levels, 40,000 1,600 will develop cancer over their lives.

There will be no difference. But its still a lot of cancer and that scares people.

Such is the case with nuclear workers around the world, people who live next to nuclear plants, downwinders from the Nevada Test Site, the people around Fukushima, nuclear workers at Hanford and other sites, and these soldiers that watched the bomb tests. These groups have no more cancers than the general population, some of them have less.

But the fear of radiation keeps growing. And that fear itself does more harm than good.

See the rest here:

Atomic Weapons Testing While Troops Looked On Did It Increase Their Cancer Risks? - Forbes

The use of targeted, biologic (immunotherapy) & other forms of therapies administered to treat cancer through oncology drugs is known as cancer therapeutics. Theglobal cancer therapeutics marketsize was valued at $98,900 million in 2018 and is estimated to reach at $180,193 million by 2026, registering a CAGR of 7.7% from 2019 to 2026.

Request For Report[emailprotected]https://www.trendsmarketresearch.com/report/sample/13204

Upsurge in collaboration between pharmaceutical companies, rise in cancer awareness & availability of oncology drugs, increase in cancer funding & research, and growth in geriatric population are the key factors that augment the growth of the cancer therapeutics market. Furthermore, rise in prevalence of cancer cases is expected to boost the market growth.

However, adverse effects associated with cancer therapeutics market and high costs associated with oncology drug development are some of the factors that impede the market growth. Conversely, the high potential of emerging economies and increase in demand for personalized medicine is expected to provide new opportunities for the market players in future.

The cancer therapeutics market is segmented based on application, top selling drugs, and region. Based on application, the market is divided into blood cancer, lung cancer, colorectal cancer, prostate cancer, breast cancer, cervical cancer, head & neck cancer, glioblastoma, malignant meningioma, mesothelioma, melanoma, and others. By top selling drugs, it is categorized into Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, Temodar and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS This report entails a detailed quantitative market analysis from 2018 to 2026 to identify the prevailing opportunities along with strategic assessment of the global cancer therapeutics market. Cancer therapeutics market size and market estimations are based on a comprehensive analysis of the applications, top selling drugs, and developments in the industry. An in-depth analysis based on region assists to understand the regional market and facilitate the strategic business planning. The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.

Get Complete TOC with Tables and[emailprotected]https://www.trendsmarketresearch.com/report/discount/13204

KEY MARKET SEGMENTS

By Applicationo Blood Cancero Lung Cancero Colorectal Cancero Prostate Cancero Breast Cancero Cervical Cancero Head and Neck Cancero Glioblastomao Malignant Meningiomao Mesotheliomao Melanomao Others

By Top Selling Drugso Revlimido Avastino Herceptino Rituxano Opdivoo Gleeveco Velcadeo Imbruvicao Ibranceo Zytigao Alimtao Xtandio Tarcevao Perjetao Temodaro Others

By Regiono North America U.S. Canadao Europe Germany France UK Italy Spain Rest of Europeo Asia-Pacific Japan China India Australia South Korea Taiwan Rest of Asia-Pacifico LAMEA Latin America Middle-East Africa

<<< Get COVID-19 Report Analysis >>>https://www.trendsmarketresearch.com/report/covid-19-analysis/13204

The list of key players operating in this market include: F. Hoffmann-La Roche AG Bristol-Myers Squibb Company AbbVie, Inc. Johnson & Johnson Celgene Corporation Astellas Pharma, Inc. Pfizer, Inc. Novartis AG Merck KGaA Eli Lilly and Company

The other players included in the value chain analysis (and not included in the report) include: AstraZeneca plc Bayer AG Takeda Pharmaceutical Company Limited

Excerpt from:

Cancer Therapeutics Market to Record a Robust Growth Rate for the COVID-19 Period - Cole of Duty

STORY FROM: COVID-19 Litigation Report

July 13, 2020

Download a PDF Version of this Article

[Editor's note: Melissa Boudreau is the Vice President of Modeling and Chief Actuary at Praedicat, a science-based data analytics company. Robert T. Reville is the Chief Executive Officer of Praedicat. This article first appeared in Carrier Management. Replies to this commentary are welcome.]

Estimates of the size of COVID-19s impact on the insurance industry vary widely, but some companies (including Chubb and Willis Re) have suggested that, considering both asset and liability losses, it will be the largest event in insurance history. In the sense of the size of industry loss, then, the coronavirus appears to be the latest candidate for the next asbestos.

Unlike asbestos, which emerged through the U.S. legal system, early estimates for general liability losses from COVID-19 are lower than the predictions from business interruption or event cancellation lines. As an infectious disease spreading widely though the population, it seems challenging to blame infections on the actions or products of specific companies. Therefore, it may, at first glance, appear destined to only result in modest losses for general liability. A deeper review of the risk, however, suggests there are some precedents that could portend a larger loss, and they come precisely from asbestos.

Many of the innovations in tort law, the underlying legal system driving liability risk, have come from asbestos. After several scientific studies in the 1960s found that insulation workers had elevated risk of asbestos-related diseases, the Eastern District of Texas court established in 1971 (Borel v. Fibreboard Paper Products) that insulation workers could sue the product manufacturers responsible for putting the asbestos in the product. This innovation in tort law launched a major wave of asbestos litigation driving general liability losses in the 1970s.

Later, numerous scientific studies found elevated rates of asbestos-related diseases among families of asbestos workers as well. A study (Vianna and Polan) in 1978, for instance, found that family members of asbestos workers were 10-times more likely to have mesothelioma than otherwise equivalent individuals. (Reference: Vianna NJ, Polan AK. Non-occupational exposure to asbestos and malignant mesothelioma in females. Lancet. 1978;1(8073):10611063. doi:10.1016/s0140-6736(78)90911-x)

Subsequently, in the mid-2000s, courts began to award damages to spouses and children of asbestos workers as well. This wave of litigation, referred to as secondary or take-home exposure lawsuits, has been an important factor in the later waves of asbestos litigation. One characteristic of the take-home asbestos litigation is that the basis of the lawsuit is the negligence of the employer itself, rather than a product defect for some supplier. As such, it potentially increases the footprint of the risk outside product exposures, and therefore doesnt just implicate the suppliers but now the employers themselves.

COVID-19 is not a product risk like asbestos. But it is an occupational risk, as workers in hospitals, nursing homes, essential retail, meat production, construction and other industries face elevated rates of transmission, magnified by stay-at-home orders that concentrate transmission within the businesses that remain open. As early as February 2020, published scientific studies from Wuhan identified one of the coronaviruss key risk characteristics as a high degree of intra-family and intra-household transmission. Frequently, workers who are not from vulnerable populations are exposed to COVID-19 at work; then family members, such as spouses or parents, are exposed at home.

Unlike transmission of COVID-19 to customers or transmission in the wider community, where a specific source of exposure may be difficult to prove, take-home COVID-19 for the parent of a nursing home worker, for instance, is relatively straightforward to connect to the specific nursing home. Furthermore, virus tracking using genetic sequencing of potentially linked infections can help associate or dissociate the worker or family members infection from other potential sources. In this sense, take-home or secondary exposure for COVID-19 is a significant phenomenon supported by science, forensics and legal precedent, and therefore may become a significant liability risk as well.

Praedicat has developed scenarios for take-home COVID-19 liability risk. We estimate that approximately 13 percent of COVID-19 deaths are family members of workers who acquired their illness at work. In a scenario where the ultimate size of the U.S. pandemic is 150,000 deaths, a level predicted by the Institute for Health Metrics and Evaluation at the time of this writing, the scenarios suggest a range of awards and settlements between $11.4 billion and $27.4 billion, depending on the degree to which courts accept this cause of action. In a catastrophic scenario where a second wave of COVID-19 cases occurs in the fall and winter and the ultimate size of the pandemic in the United States is 300,000 deaths, the losses could exceed $50 billion.

These losses would be broadly spread across industries ranging from healthcare to retail and would involve companies of all sizes. If these losses emerge and are covered by insurance, general liability alone will elevate COVID-19 to next asbestos levels.

Take-home asbestos liability has not been uniformly accepted by courts across the United States. Indeed, New York State, which has seen the largest number of COVID-19 deaths, rejected take-home asbestos liability. Other states with large numbers of cases, including Washington, California, New Jersey and Louisiana, have accepted it.

We do not know if take-home COVID-19 will be interpreted the same way as take-home asbestos. Even if the cause of action is accepted, the question of coverage on general liability is unclear, as there may be infectious disease exclusions or the pollution exclusion may apply. There may even be liability protections or alternative compensation mechanisms enacted in various states to assist the recovery from COVID-19s economic impact. Nonetheless, given the social inflation environment that existed as COVID-19 emerged, it is reasonable that insurers should prepare for an adverse take-home COVID-19 liability landscape while hoping for the best.

View original post here:

Article - The Risk of 'Take-Home' COVID-19 and the 'Next Asbestos' - HarrisMartin Publishing

In developed countries, discretionary research funding for cancer is on a rise. Increased investments towards development of better treatment against malignant mesothelioma is observed globally. Persistence Market Researchs new report on global market for malignant mesothelioma predicts that governments will increase their focus towards creating awareness about mesothelioma in the future.

The globalmalignant mesothelioma marketis expected to incur favorable boost from increased healthcare spending witnessed in multiple parts of the world, coupled with availability of better treatment prognosis for mesothelioma.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/10628

Company Profiles

In 2017, the global malignant mesothelioma market is expected to reach a value of US$ 338 Mn. The report observes that increasing use of asbestos for commercial purposes is fuelling the incidence of malignant mesothelioma among people.

By the end of 2025, the global market for malignant mesothelioma is anticipated to have soared at 7.5% CAGR, reaching an estimated US$ 604 Mn in value.

Global Malignant Mesothelioma Market Prominent Trends

Studies focused on cause of malignant mesothelioma are being publicized to boost awareness. Through such work, people are becoming more aware, particularly with respect to association of the HOXB4 gene is stopping the maturation of mesothelioma tumor.

Overall, the global market for malignant mesothelioma is also witnessing an increased adoption of combination therapies. Many companies are promoting the cumulative use of chemotherapy and immune-oncology procedures in treatment of malignant mesothelioma.

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/10628

In addition to this, malignant mesothelioma is gaining incidence among men. Exposure to asbestos is likely to remain concentrated to male demographics of the world. Increased exposure to such toxic elements is aggravating the incidence of mesothelioma in men.

Key players in the global malignant mesothelioma market are also collaborating with leading research organizations to develop combination drugs on mesothelioma, the approval of which is drawing highest regard of authorities such as the FDA.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/10628

Malignant Mesothelioma Market Forecast Key Findings

Visit link:

COVID-19 Analysis | Malignant Mesothelioma Market by Trends, Dynamic Innovation in Technology and 2025 Forecasts - Jewish Life News

Malignant Mesothelioma Market 2018: Global Industry Insights by Global Players, Regional Segmentation, Growth, Applications, Major Drivers, Value and Foreseen till 2024

The recent published research report sheds light on critical aspects of the global Malignant Mesothelioma market such as vendor landscape, competitive strategies, market drivers and challenges along with the regional analysis. The report helps the readers to draw a suitable conclusion and clearly understand the current and future scenario and trends of global Malignant Mesothelioma market. The research study comes out as a compilation of useful guidelines for players to understand and define their strategies more efficiently in order to keep themselves ahead of their competitors. The report profiles leading companies of the global Malignant Mesothelioma market along with the emerging new ventures who are creating an impact on the global market with their latest innovations and technologies.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.researchmoz.com/enquiry.php?type=S&repid=2720072&source=atm

The recent published study includes information on key segmentation of the global Malignant Mesothelioma market on the basis of type/product, application and geography (country/region). Each of the segments included in the report is studies in relations to different factors such as market size, market share, value, growth rate and other quantitate information.

The competitive analysis included in the global Malignant Mesothelioma market study allows their readers to understand the difference between players and how they are operating amounts themselves on global scale. The research study gives a deep insight on the current and future trends of the market along with the opportunities for the new players who are in process of entering global Malignant Mesothelioma market. Market dynamic analysis such as market drivers, market restraints are explained thoroughly in the most detailed and easiest possible manner. The companies can also find several recommendations improve their business on the global scale.

The readers of the Malignant Mesothelioma Market report can also extract several key insights such as market size of varies products and application along with their market share and growth rate. The report also includes information for next five years as forested data and past five years as historical data and the market share of the several key information.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2720072&source=atm

segment by Type, the product can be split intoOralParenteralMarket segment by Application, split intoHospital PharmaciesRetail PharmaciesOncology CentersOther

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2720072&licType=S&source=atm

Some of the Major Highlights of TOC covers in Malignant Mesothelioma Market Report:

Chapter 1: Methodology & Scope of Malignant Mesothelioma Market

Chapter 2: Executive Summary of Malignant Mesothelioma Market

Chapter 3: Malignant Mesothelioma Industry Insights

Chapter 4: Malignant Mesothelioma Market, By Region

Chapter 5: Company Profile

And Continue

Read the rest here:

Malignant Mesothelioma Market: Quantitative Analysis From 2019 To 2023 To Enable The Stakeholders To Capitalize On The Prevailing Market Opportunities...

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today announced that over 100 physicians from more than 50 cancer treatment centers in the U.S. are now certified to prescribe Optune Lua, which is approved for the first-line treatment of unresectable, locally advanced or metastatic malignant pleural mesothelioma (MPM), in combination with pemetrexed and platinum-based chemotherapy.

This is a disease with a poor prognosis, so being able to offer patients a therapy that results in excellent response rates with minimal toxicity is exciting, said Matthew T. Ballo, M.D., FACR, Professor and Chair, Department of Radiation Oncology, West Cancer Center & Research Institute in Germantown, Tennessee. We as clinicians can have a big impact on our patients lives by making them aware of this important new technology.

We are proud of the progress we have made in the last year in making Optune Lua accessible to patients, said Pritesh Shah, Novocures Chief Commercial Officer. We continue to work diligently to expand the number of centers that can provide Tumor Treating Fields therapy to patients facing this devastating and aggressive disease.

Of the more than 50 certified centers, 28 are now offering Optune Lua to MPM patients. The remaining centers are in the process of completing all regulatory requirements.

For a complete list of centers where Optune can be prescribed, please visit OptuneLuaCenters.com.

About Optune Lua

Optune Lua is a noninvasive, antimitotic cancer treatment for MPM. Optune Lua delivers Tumor Treating Fields to the region of the tumor.

Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and causing affected cancer cells to die. Tumor Treating Fields does not stimulate or heat tissue and targets dividing cancer cells of a specific size. Tumor Treating Fields causes minimal damage to healthy cells. Mild to moderate skin irritation is the most common side effect reported. Tumor Treating Fields is approved in certain countries for the treatment of adults with glioblastoma and in the U.S. for mesothelioma, two of the most difficult cancer types to treat. The therapy shows promise in multiple solid tumor types including some of the most aggressive forms of cancer.

Caution: Federal law restricts this device to sale by or on the order of a physician. Humanitarian Device. Authorized by Federal Law for use in the treatment of adult patients with unresectable, locally advanced or metastatic, malignant pleural mesothelioma concurrently with pemetrexed and platinum-based chemotherapy. The effectiveness of this device for this use has not been demonstrated.

Approved Indications

Optune Lua is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic, malignant pleural mesothelioma (MPM) to be used concurrently with pemetrexed and platinum-based chemotherapy.

Important Safety Information

Contraindications

Do not use Optune Lua in patients with implantable electronic medical devices such as pacemakers or implantable automatic defibrillators, etc. Use of Optune Lua together with implanted electronic devices has not been tested and may lead to malfunctioning of the implanted device.

Do not use Optune Lua in patients known to be sensitive to conductive hydrogels. Skin contact with the gel used with Optune Lua may commonly cause increased redness and itching, and may rarely lead to severe allergic reactions such as shock and respiratory failure.

Warnings and Precautions

Optune Lua can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure.

The most common (10%) adverse events involving Optune Lua in combination with chemotherapy were anemia, constipation, nausea, asthenia, chest pain, fatigue, medical device site reaction, pruritus, and cough.

Other potential adverse effects associated with the use of Optune Lua include: treatment related skin toxicity, allergic reaction to the plaster or to the gel, electrode overheating leading to pain and/or local skin burns, infections at sites of electrode contact with the skin, local warmth and tingling sensation beneath the electrodes, muscle twitching, medical device site reaction and skin breakdown/skin ulcer.

If the patient has an underlying serious skin condition on the treated area, evaluate whether this may prevent or temporarily interfere with Optune Lua treatment.

Do not prescribe Optune Lua for patients that are pregnant, you think might be pregnant or are trying to get pregnant, as the safety and effectiveness of Optune Lua in these populations have not been established.

Please visit http://www.optunelua.com to see Optune Lua Instructions For Use (IFU) for complete information regarding the devices indications, contraindications, warnings, and precautions.

About Novocure

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocures commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and in the U.S. for the treatment of adult patients with malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and gastric cancer.

Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City. Additionally, the company has offices in Germany, Switzerland, Japan and Israel. For additional information about the company, please visit http://www.novocure.com or follow us at http://www.twitter.com/novocure.

Forward-Looking Statements

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocures current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as anticipate, estimate, expect, project, intend, plan, believe or other words and terms of similar meaning. Novocures performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions as well as more specific risks and uncertainties facing Novocure such as those set forth in its Report on Form 10-K filed on February 27, 2020, with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.

Excerpt from:

Novocure Announces Over 100 Physicians in the U.S. Now Certified to Prescribe Optune Lua - Business Wire

A new study published by the Science Translational Medicine journal showed that, for a small cohort, LMB-100 could be even more effective when paired with Keytruda for treating patients with mesothelioma. Researchers saw a median survival rate of almost a year, with a handful of clinical trial participants continuing to show progress after more than three years.

Following this success, the National Cancer Institute is currently accepting clinical trial participants for phase 2 of the study.

LMB-100 is an immunotoxin drug designed to help the immune system find and destroy cancer and mesothelioma cells.

Keytruda, an antibody drug used in cancer immunotherapy manufactured by Merck and also known as Pembrolizumab, hasbeen approved by the FDAover the years for several treatments includingsolid tumor cancers and non-small cell lung cancer.

The study showed that patients taking both LMB-100 and Keytruda (pembrolizumab) could result in more effective treatment.

In some of the patients, receiving pembrolizumab after LMB-100 resulted in greater efficacy than what would be expected from pembrolizumab alone, said Raffit Hassan, M.D., Chief of the Thoracic and GI Malignancies Branch at the National Cancer Institute.

Patients diagnosed withmalignant mesotheliomaare encouraged to speak with their oncologist or consult with aMesothelioma Center of Excellenceto determine whether Keytruda or other medications can be an effective treatment,or whether they might be a candidate for aclinical trial. We at MesotheliomaHelp.org arealways availableto assist you.

Read more:

New Study Shows LMB-100 Can Be Even More Effective Paired with Keytruda for Mesothelioma Treatment - MesotheliomaHelp.org

Malignant Mesothelioma MarketLatest Research Report 2020:

The Malignant Mesothelioma report provides an independent information about the Malignant Mesothelioma industry supported by extensive research on factors such as industry segments size & trends, inhibitors, dynamics, drivers, opportunities & challenges, environment & policy, cost overview, porters five force analysis, and key companies

Download Premium Sample Copy Of This Report:Download FREE Sample PDF!

In this report, our team offers a thorough investigation of Malignant Mesothelioma Market, SWOT examination of the most prominent players right now. Alongside an industrial chain, market measurements regarding revenue, sales, value, capacity, regional market examination, section insightful information, and market forecast are offered in the full investigation, and so forth.

Scope of Malignant Mesothelioma Market: Products in the Malignant Mesothelioma classification furnish clients with assets to get ready for tests, tests, and evaluations.

Major Company Profiles Covered in This Report

Company I, Company II, Company III, Company IV and more

Malignant Mesothelioma Market Report Covers the Following Segments:

Segment by Type:Type I, Type II, Type III

Segment by Application:Application I, Application II, Application III

North America

Europe

Asia-Pacific

South America

Center East and Africa

United States, Canada and Mexico

Germany, France, UK, Russia and Italy

China, Japan, Korea, India and Southeast Asia

Brazil, Argentina, Colombia

Saudi Arabia, UAE, Egypt, Nigeria and South Africa

Market Overview:The report begins with this section where product overview and highlights of product and application segments of the global Malignant Mesothelioma Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition by Company:Here, the competition in the Worldwide Malignant Mesothelioma Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data:As the name suggests, this section gives the sales data of key players of the global Malignant Mesothelioma Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the global Malignant Mesothelioma Market.

Market Status and Outlook by Region:In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the global Malignant Mesothelioma Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User:This section of the research study shows how different end-user/application segments contribute to the global Malignant Mesothelioma Market.

Market Forecast:Here, the report offers a complete forecast of the global Malignant Mesothelioma Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion:This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Top Trending Reports:

https://brandessenceresearch.com/consumer-goods/global-beard-oil-market

https://brandessenceresearch.com/healthcare/aromatherapy-market-incredible-possibilities

https://brandessenceresearch.com/healthcare/vascular-access-devices-market

https://brandessenceresearch.com/healthcare/vascular-access-devices-market

https://www.marketwatch.com/press-release/us-mattress-market-global-trends-market-share-industry-size-growth-opportunities-and-market-forecast-2020-to-2025-2020-04-10

Top Trending Reports:

https://www.marketwatch.com/press-release/ear-nose-throat-ent-devices-market-ent-devices-industry-size-2025-2020-07-07

https://www.marketwatch.com/press-release/sourcing-software-market-to-grow-at-a-moderate-pace-till-2025-end-2020-07-07

https://www.marketwatch.com/press-release/at-132-cagr-antibody-production-market-size-to-surpass-usd-2246-billion-by-2025-2020-07-07

https://www.marketwatch.com/press-release/impact-of-covid-19-global-veterinary-health-products-market-2020-to-2025-bayer-elanco-merck-merial-zoetis-inc-biogenesis-bago-sa-2020-07-07

https://www.marketwatch.com/press-release/software-outsourcing-market-size-share-latest-technology-advancements-future-growth-and-developments-2020-to-2025-covid-19-impact-analysis-bmrc-2020-07-07

Read more:

Malignant Mesothelioma Market Strategies and Insight Driven Transformation 2020-2025 - Jewish Life News

You probably dont think about asbestos exposure very often. The EPA banned its use in 1989, and after all the news articles about how asbestos causes cancer and mesothelioma, who would want to use it at all?

But the ban was removed a few years later, and while contractors virtually never use asbestos in residential applications anymore, it remains in millions of homes, especially those built before the 1970s.

Although asbestos in the home usually doesnt pose a day-to-day danger, homeowners need to know the dangers involved in disturbing it, the consequences of asbestos exposure and the proper methods for asbestos removal.

Due to its heat resistance and strength, asbestos was used in a wide variety of construction purposes such as flooring, drywall and insulation. Basement pipe insulation and tape on old duct work are among the most common places youll find dangerous asbestos, because it breaks up over time and all of it is several decades old.

You cant see or smell asbestos. The only way to be sure is to hire an environmental consulting firm or asbestos building inspector for asbestos testing. Theyll take fingernail-sized samples and test them in a laboratory. This work will usually cost between $100 and $700, depending on how extensive the testing is.

Some asbestos materials, such as flooring, are best left undisturbed. If you plan on doing work that involves breaking up, removing or drilling through those materials, though, call an asbestos professional. Asbestos removal is not federally regulated, but most states require licensing.

Deteriorating materials such as tape and pipe insulation should be replaced. A qualified professional will use specialized techniques to seal off the area and prevent any asbestos from escaping. A typical project takes two people eight hours to complete.

Popcorn ceilings installed before 1990 are likely to have asbestos in it. Asbestos popcorn ceiling removal costs between $3 and $10 per square foot two to three times as much as standard popcorn ceiling removal.

Preparing the area and sealing it off from the outside makes up two-thirds of asbestos abatement cost. Expect to pay between $75 and $200 per hour for labor.

Hiring asbestos removal contractors should be done carefully. Asbestos licensing and training regulations vary by state and locality. Learn your local laws and verify that they have the appropriate licenses and, if necessary, the permits required for the job.

Read more here:

Here's what you should know about asbestos in your home - Seattle Times

By Paul F. P. Pogue, Angies List Published 5:05 p.m. ET July 9, 2020

You probably dont think about asbestos exposure very often. The EPA banned its use in 1989, and after all the news articles about how asbestos causes cancer and mesothelioma, who would want to use it at all? But the ban was removed a few years later, and while contractors virtually never use asbestos in residential applications anymore, it remains in millions of homes, especially those built before the 1970s.

Although asbestos in the home usually doesnt pose a day-to-day danger, homeowners need to know the dangers involved in disturbing it, the consequences of asbestos exposure and the proper asbestos removal methods.

Due to its heat resistance and strength, asbestos was used in a wide variety of construction purposes such as flooring, drywall and insulation. Basement pipe insulation and tape on old duct work are among the most common places youll find dangerous asbestos, because it breaks up over time and all of it is several decades old.

Asbestos can be found in a wide array of residential applications from the 1960s and earlier, including flooring, pipe insulation and roofing. Asbestos is most dangerous when the materials are broken up.(Photo: Dreamstime, TNS)

You cant see or smell asbestos. The only way to be sure is to hire an environmental consulting firm or asbestos building inspector for asbestos testing. Theyll take fingernail-sized samples and test them in a laboratory. This work will cost between $100 and $700, depending on how extensive the testing is.

Hiring an asbestos removal contractor

Some asbestos materials, such as flooring, are best left undisturbed. If you plan on doing work that involves breaking up, removing or drilling through those materials, though, call an asbestos professional. Asbestos removal is not federally regulated, but most states require licensing.

Deteriorating materials such as tape and pipe insulation should be replaced. A qualified professional will use specialized techniques to seal off the area and prevent any amount of asbestos from escaping. A typical project takes two people eight hours to complete.

Popcorn ceiling installed prior to 1990 is likely to have asbestos in it. Asbestos popcorn ceiling removal costs between $3 and $10 per square foot two to three times as much as standard popcorn ceiling removal.

Most asbestos removal jobs will cost between $1,000 and $3,000. More extensive jobs, such as a whole-house remediation, will be much more expensive, averaging between $15,000 and $30,000.

Preparing the area and sealing it off from the outside makes up two-thirds of asbestos abatement cost. Expect to pay between $75 and $200 per hour for labor.

Hiring asbestos removal contractors should be done carefully. Asbestos licensing and training regulations vary by state and locality. Learn your local laws and verify that they have the appropriate licenses and, if necessary, the permits required for the job.

Paul F. P. Pogue is a reporter for Angies List, a trusted provider of local consumer reviews and an online marketplace of services from top-rated providers. Visit AngiesList.com.

Read or Share this story: https://www.detroitnews.com/story/life/home-garden/2020/07/09/angies-list-what-do-need-know-asbestos-my-home/5391244002/

Read the original here:

Angies List: What do I need to know about asbestos in my home? - The Detroit News

You probably dont think about asbestos exposure very often. The EPA banned its use in 1989, and after all the news articles about how asbestos causes cancer and mesothelioma, who would want to use it at all?

But the ban was removed a few years later, and while contractors virtually never use asbestos in residential applications anymore, it remains in millions of homes, especially those built before the 1970s.

Although asbestos in the home usually doesnt pose a day-to-day danger, homeowners need to know the risks involved in disturbing it, the consequences of asbestos exposure and the proper asbestos removal methods.

Due to its heat resistance and strength, asbestos was used for a wide variety of construction purposes such as flooring, drywall and insulation. Basement pipe insulation and tape on old duct work are among the most common places youll find dangerous asbestos, because it breaks up over time and all of it is several decades old.

You cant see or smell asbestos fibers. The only way to be sure is to hire an environmental consulting firm or asbestos building inspector for asbestos testing. Theyll take fingernail-sized samples and test them in a laboratory. This work will cost between $100 and $700, depending on how extensive the testing is.

Some asbestos materials, such as flooring, are best left undisturbed. If you plan on doing work that involves breaking up, removing or drilling through those materials, though, call an asbestos professional. Asbestos removal is not federally regulated, but most states require licensing.

Deteriorating materials such as tape and pipe insulation should be replaced. A qualified professional will use specialized techniques to seal off the area and prevent any amount of asbestos from escaping. A typical project takes two people eight hours to complete.

Popcorn ceiling installed prior to 1990 is likely to have asbestos in it. Asbestos popcorn ceiling removal costs between $3 and $10 per square foot two to three times as much as standard popcorn ceiling removal.

Most asbestos removal jobs will cost between $1,000 and $3,000. More extensive jobs, such as a whole-house remediation, will be much more expensive, averaging between $15,000 and $30,000. Preparing the area and sealing it off from the outside makes up two-thirds of asbestos abatement cost.

Hiring asbestos removal contractors should be done carefully. Asbestos licensing and training regulations vary by state and locality.

Learn your local laws and verify that they have the appropriate licenses and, if necessary, the permits required for the job.

Paul F. P. Pogue is a reporter for Angies List, a trusted provider of local consumer reviews and an online marketplace of services from top-rated providers. Visit AngiesList.com.

See the original post here:

What do I need to know about asbestos in my home? - The Union Leader

This article was originally published here

Wang X, et al. J Radiat Res 2020.

ABSTRACT

Targeted alpha therapy (TAT) is a promising tumor therapy that can specifically transport particle to the vicinity of tumor cells while the normal cells are only slightly irradiated. Mesothelin is a highly promising molecular signature for many types of solid tumors including malignant mesothelioma, pancreatic cancer, ovarian cancer and lung adenocarcinoma etc., while the expression in normal human tissues are limited, thus making mesothelin a promising antigen for TAT. Previously we developed a theoretical model that could predict and optimize in vitro screening of potential TAT drugs. The aim of the study is construction and preclinical evaluation of 211At labeled anti-mesothelin antibodies as potential TAT drugs. Mesothelin expression of two tumor cell lines were confirmed by flow cytometry, and their radiosensitivities were also evaluated. We used two kinds of anti-mesothelin antibodies, ET210-6 and ET210-28, to construct TAT drugs. Then, radiochemical purity, stability in vitro, affinity of the conjugates and mesothelin expression level were assessed. The specific killing of mesothelin-positive cancer cells treated by 211At-ET210-28 and 211At-ET210-6 were studied via Cell Counting Kit-8 assay and colony formation assay. 211At-ET210-28 and 211At-ET210-6 revealed excellent affinity and stability in both phosphate buffer saline and fetal bovine serum environment. Radiolabeled antibody conjugates bound specifically to mesothelin-positive cells in vitro. Both 211At-ET210-28 and 211At-ET210-6 could specifically kill mesothelin-positive cells with negligible damages to mesothelin-negative cells. Our findings provide initial proof-of-concept for the potential use of 211At labeled ET210-28/ET210-6 anti-mesothelin antibody in specific killings of mesothelin-positive tumor cells.

PMID:32648573 | DOI:10.1093/jrr/rraa049

Originally posted here:

Construction and Preclinical Evaluation of 211At Labeled Anti-mesothelin Antibodies as Potential Targeted Alpha Therapy Drugs - DocWire News

Published on June 17, 2020

When a patient is suspected of having malignant pleural mesothelioma, speed is of the essence. The physicians goal is to confirm the diagnosis as quickly as possible so that they can devise the most effective treatment protocol for the patients specific condition. One of the most frequently-used tools in staging this rare and fatal form of cancer is to take a tissue sample from the tumor via video-assisted thoracospic surgery, or VATS. Though this video-assisted pleural biopsy has long been highly regarded, a new study out of Japan has revealed significant weaknesses in its accuracy.

Though most oncologists will quickly order a video-assisted pleural biopsy when malignant pleural mesothelioma is suspected, oncologists at Hyogo College of Medicine in Japan have recently conducted research on 400 patients suspected of having the aggressive form of asbestos-related cancer, and have found significant vulnerabilities in the accuracy of its results.

Though the cancer doctors found that video-assisted pleural biopsy correctly identified mesothelioma in many patients, those who are in the earliest stages of the disease or whose bodies are reacting with a significant amount of inflammation or growths of fibrous connective tissue around the tumor had a high likelihood of being misdiagnosed. These misdiagnoses can often lead to delays in much-needed treatment.

Though the Japanese researchers did not conclude that video-assisted pleural biopsy should be entirely abandoned when malignant pleural mesothelioma is suspected, they did warn physicians who may order the test that though it is advantageous due to its minimally-invasive approach, there are many situations where it falls short of the specific patients needs.

In the case of this study, of the 400 patients tested for pleural mesothelioma between 2004 and 2017, roughly 70 percent had that diagnosis confirmed by the testing, but ten percent were misdiagnosed. Approximately 102 were diagnosed with either atypical mesothelial proliferation or non-specific pleuritis, and 9.8 percent of those diagnoses were incorrect and later diagnosed as malignant mesothelioma.

If you or someone you love has been exposed to asbestos and begins to show symptoms suggestive of malignant mesothelioma, then getting accurate diagnostic testing is one of the most important steps you can take. For more information on access to crucial medical resources, contact the Patient Advocates at Mesothelioma.net today at1-800-692-8608.

Learn more about and contact Terri

Read more from the original source:

Study Reveals Weakness of Vide-Assisted Pleural Biopsy for Mesothelioma Diagnosis - Mesothelioma.net Blog

Published on June 18, 2020

Following confirmation of positive results, the U.S. Food and Drug Administration has approved the use of the immunotherapy drug pembrolizumab (Keytruda) for patients diagnosed with unresectable or metastatic malignant mesothelioma, as well as other solid tumor cancers.

The approval was specifically provided for patients with mesothelioma tumors and other tumors that contain levels of tissue tumor mutation that are considered high as determined by an FDA-approved test, whose disease has progressed despite having received other treatments and for whom there are no good alternatives available.

In explaining its rationale for approval of the innovative treatment, the FDA issued a press release indicating that clinical trials had shown a response rate of 29% in patients with mesothelioma and other tumors who demonstrated this particular mutation biomarker level. The agency referred to these results as quite impressive, and particularly in light of the challenges presented by these diseases.

The FDA has indicated that the approval of Keytruda for use in mesothelioma is contingent upon verification of clinical benefit in future trials, and reports that the approval is supported by findings from an analysis of 10 cohorts of patients. The results were notably better than what was found in patients whose tumor mutation levels were not categorized as high.

The positive results gathered from the ten cohorts showed complete responses in 4% of patients and partial responses in 25%. More than half of the patients in the study were able to gain a benefit for at least one year, and half of that group had responses of at least two years. Speaking of the approval, Roy S. Herbst, MD, PhD, ensign professor of medicine (medical oncology) and professor of pharmacology, Yale School of Medicine; chief of medical oncology, Yale Cancer Center and Smilow Cancer Hospital; and associate cancer center director for translational research, Yale Cancer Center, said, As physicians, we are always looking to find new options for patients, especially in the second-line or higher treatment setting. Its great to see the use of innovative biomarkers and immunotherapy come together with this approval and encouraging that we now have an option for patients with TMB-H tumors across cancer types, including rare cancers.

For mesothelioma patients, news of expanded treatment options approved by the FDA is very encouraging. For information on treatment centers offering state of the art options, contact the Patient Advocates at Mesothelioma.net today at1-800-692-8608.

Learn more about and contact Terri

Originally posted here:

FDA Provides Approval of Keytruda For Treatment of Mesothelioma and Other Tumors - Mesothelioma.net Blog

Most clinical trials experimenting with novel treatments focus on pleural mesothelioma, due to the higher incidence rates and poorer prognosis. Peritoneal mesothelioma often gets little attention.

One study combining two mesothelioma immunotherapy drugs is the anomaly to that truth.

Researchers from the MD Anderson Cancer Center in Houston, Texas, are analyzing the effects of atezolizumab and bevacizumab. Atezolizumab is an anti-PD-L1 drug, and bevacizumab is an anti-VEGF treatment.

Together they are called AtezoBev, and they showed promising results in a recent phase 2 clinical trial.

If you want to learn more about peritoneal mesothelioma treatment options, reach out to our medical staff. Our registered nurse, Jenna Campagna, can provide insight into the best methods for treating your individual diagnosis. Email her at jenna@mesotheliomaguide.com.

The standard treatment for peritoneal mesothelioma is cytoreduction with heated intraperitoneal chemotherapy (HIPEC). According to numerous studies, this approach can lead to survival times of between three and five years.

However, mesothelioma recurrence is frequent due to the makeup of the disease. Microscopic tumors fill the peritoneum, which is the small membrane covering the abdominal cavity, along with the abdominal cavity itself. Removing all of them during surgery is challenging.

Additionally, some patients might not be eligible for cytoreduction with HIPEC. Their cancer may resist traditional chemotherapy, which is typical for mesothelioma. Any treatment that may reduce tumor size prior to surgery or extend life for non-surgical patients should be investigated.

The atezolizumab and bevacizumab study included many types of cancers, including both peritoneal mesothelioma and pleural mesothelioma. It involved 160 patients, of which 20 had peritoneal mesothelioma. Patients received both atezolizumab and bevacizumab for 60 minutes once every three weeks, so long as the disease did not progress.

The American Society of Clinical Oncology analyzed the effectiveness of AtezoBev just among those 20 participants with peritoneal mesothelioma. Seven of the 20 (35%) experienced at least a minimal reduction in tumor size, which surpasses the original goal of just 11%.

Long-term follow-ups showed substantial benefits of AtezoBev:

Atezolizumab and bevacizumab work in distinctly different ways, but they have the same goal: mesothelioma cell death.

Atezolizumab prevents a connection that helps mesothelioma cells survive. These infected cells have a protein called PD-L1, which can subdue the bodys T-cells. These disease-fighting cells have the protein PD-1. When the two protein receptors link, the T-cells are inhibited from accurately assessing mesothelioma cells as dangerous.

Atezolizumab breaks this link and acts as a wall between the receptors. Its presence allows the T-cells to recognize mesothelioma cells as dangerous.

Bevacizumab, the generic name for the brand drug Avastin, subdues another mesothelioma protein called VEGF (vascular endothelial growth factor). This protein stimulates the creation of new blood vessels, a process called angiogenesis.

All cells, even cancerous ones, need to receive oxygen and nutrients to survive. Making new blood vessels is how mesothelioma tumors grow and spread through the body. Bevacizumab blocks this protein and can prevent mesothelioma cells from receiving oxygen and nutrients.

Show Sources & Author

Devin Golden is the content writer for Mesothelioma Guide. He produces mesothelioma-related content on various mediums, including the Mesothelioma Guide website and social media channels. Devin's objective is to translate complex information regarding mesothelioma into informative, easily absorbable content to help patients and their loved ones.

Get in depth knowledge about your diagnosis & the best treatments.

Learn More

Go here to see the original:

Immunotherapy Combination Proving Effective for Peritoneal Mesothelioma - Mesothelioma Guide

COVID-19 Impact Analysis of Malignant Mesothelioma Market

[Los Angeles], [United States], June 2020, The Malignant Mesothelioma Market research report includes an in-sight study of the key [Global Malignant Mesothelioma Market Size, Status and Forecast 2020-2026] market prominent players along with the company profiles and planning adopted by them. This helps the buyer of the Malignant Mesothelioma report to gain a clear view of the competitive landscape and accordingly plan Malignant Mesothelioma market strategies. An isolated section with top key players is provided in the report, which provides a complete analysis of price, gross, revenue(Mn), Malignant Mesothelioma specifications, and company profiles. The Malignant Mesothelioma study is segmented by Module Type, Test Type, And Region.

The market size section gives the Malignant Mesothelioma market revenue, covering both the historic growth of the market and the forecasting of the future. Moreover, the report covers a host of company profiles, who are making a mark in the industry or have the potential to do so. The profiling of the players includes their market size, key product launches, information regarding the strategies they employ, and others. The report identifies the total market sales generated by a particular firm over a period of time. Industry experts calculate share by taking into account the product sales over a period and then dividing it by the overall sales of the Malignant Mesothelioma industry over a defined period.

Download Full PDF Sample Copy of Report: https://www.qyresearch.com/sample-form/form/1531346/global-malignant-mesothelioma-market

Key Manufacturers of Malignant Mesothelioma Market include: AstraZeneca, Bristol-Myers Squibb, Roche, Merck, Novartis, Pfizer, Sanofi, Eli Lilly, Teva Pharmaceuticals, Boehringer Ingelheim GmbH, Mylan, Fresenius Kabi, Sun Pharmaceuticals, Corden Pharma, Concordia International, Kyowa Hakko Kirin, Polaris Pharmaceuticals, MolMed, Ono Pharmaceutical, Nichi-Iko Pharmaceutical Malignant Mesothelioma

The research covers the current market size of the [Global Malignant Mesothelioma Market Size, Status and Forecast 2020-2026]and its growth rates based on 5 year history data. It also covers various types of segmentation such as by geography North America, Europe, Asia-Pacific etc.,. The in-depth information by segments of Malignant Mesotheliomamarket helps monitor performance & make critical decisions for growth and profitability. It provides information on trends and developments, focuses on markets and materials, capacities, technologies, CAPEX cycle and the changing structure of the [Global Malignant Mesothelioma Market Size, Status and Forecast 2020-2026].

This study also contains company profiling, product picture and specifications, sales, market share and contact information of various international, regional, and local vendors of [Global Malignant Mesothelioma Market Size, Status and Forecast 2020-2026]. The market competition is constantly growing higher with the rise in technological innovation and M&A activities in the industry. Moreover, many local and regional vendors are offering specific application products for varied end-users. The new vendor entrants in the market are finding it hard to compete with the international vendors based on quality, reliability, and innovations in technology.

Read Detailed Index of full Research Study: https://www.qyresearch.com/index/detail/1531346/global-malignant-mesothelioma-market

Geographically,this report is segmented into several key Regions, with production, consumption, revenue (million USD), and market share and growth rate of Malignant Mesotheliomain these regions, from 2012 to 2022 (forecast), covering

Please Check below Chapters to display the [Global Malignant Mesothelioma Market Size, Status and Forecast 2020-2026].

There are 15 Chapters to display the [Global Malignant Mesothelioma Market Size, Status and Forecast 2020-2026].

Request for customization in Report and get it within 24 hours in your inbox: https://www.qyresearch.com/customize-request/form/1531346/global-malignant-mesothelioma-market

Table of Contents:

Chapter 1, to describe Definition, Specifications and Classification of Malignant Mesothelioma, Applications of Malignant Mesothelioma, Market Segment by Regions;

Chapter 2, To analyse the Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure;

Chapter 3, to display the Technical Data and Manufacturing Plants Analysis of Malignant Mesothelioma, Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis;

Chapter 4, to show the Overall Market Analysis, Capacity Analysis (AstraZeneca, Bristol-Myers Squibb, Roche, Merck, Novartis, Pfizer, Sanofi, Eli Lilly, Teva Pharmaceuticals, Boehringer Ingelheim GmbH, Mylan, Fresenius Kabi, Sun Pharmaceuticals, Corden Pharma, Concordia International, Kyowa Hakko Kirin, Polaris Pharmaceuticals, MolMed, Ono Pharmaceutical, Nichi-Iko Pharmaceutical Malignant Mesothelioma ), Sales Analysis (AstraZeneca, Bristol-Myers Squibb, Roche, Merck, Novartis, Pfizer, Sanofi, Eli Lilly, Teva Pharmaceuticals, Boehringer Ingelheim GmbH, Mylan, Fresenius Kabi, Sun Pharmaceuticals, Corden Pharma, Concordia International, Kyowa Hakko Kirin, Polaris Pharmaceuticals, MolMed, Ono Pharmaceutical, Nichi-Iko Pharmaceutical Malignant Mesothelioma ), Sales Price Analysis (AstraZeneca, Bristol-Myers Squibb, Roche, Merck, Novartis, Pfizer, Sanofi, Eli Lilly, Teva Pharmaceuticals, Boehringer Ingelheim GmbH, Mylan, Fresenius Kabi, Sun Pharmaceuticals, Corden Pharma, Concordia International, Kyowa Hakko Kirin, Polaris Pharmaceuticals, MolMed, Ono Pharmaceutical, Nichi-Iko Pharmaceutical Malignant Mesothelioma );

Chapter 5 and 6, to show the Regional Market Analysis that includes North America, Europe, Asia-Pacific etc., Malignant Mesothelioma Segment Market Analysis;

Chapter 7 and 8, to analyse the Malignant Mesothelioma Segment Market Analysis Major Manufacturers Analysis of Malignant Mesothelioma;

Chapter 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type, Market Trend;

Chapter 10, Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis;

Chapter 11, to analyse the Consumers Analysis of Malignant Mesothelioma;

Chapter 12, to describe Malignant Mesothelioma Research Findings and Conclusion, Appendix, methodology and data source;

Chapter 13, 14 and 15, to describe Malignant Mesothelioma sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

About Us:

QY Research established in 2007, focus on custom research, management consulting, IPO consulting, industry chain research, data base and seminar services. The company owned a large basic data base (such as National Bureau of statistics database, Customs import and export database, Industry Association Database etc), experts resources (included energy automotive chemical medical ICT consumer goods etc.

Read more from the original source:

Malignant Mesothelioma Market Emerging Trends, Global Demand and Business Opportunities 2020 to 2026 - 3rd Watch News

This page has been fact checked by aDoctor of Nursing Practice who specializes in Oncology and has experience working with mesothelioma patients.

Sources of information are listed at the bottom of the article. We make every attempt to keep our information accurate and up-to-date.

Please Contact Us with any questions or comments.

Palliative treatment is especially important for mesothelioma patients who often live with severe side effects and symptoms, distress, anxiety, and fear. More than just treating the disease, palliative care is supportive care for the person as a whole and aims to improve their quality of life for as long as possible.

Palliative treatment is any type of care provided for a patient with a serious or terminal illness with the goal of improving quality of life. Instead of solely treating a disease, it focuses on factors that affect symptoms as well prioritizing personalized care. Treatment is geared towards what matters most to patients. This includes all kinds of supportive care:

While there may be some overlap in strategies, palliative care is not the same as other cancer treatments. The goal of treatments that are not palliative is to cure, slow, or stop the progression of a disease. Many patients with mesothelioma benefit from both palliative and non-palliative treatments.

Studies find that malignant mesothelioma patients have a high burden of symptoms. In one study, for instance, 92 percent of patients lived with three or more difficult symptoms: shortness of breath, fatigue, chest pains, loss of appetite, and cough, among other less common symptoms. They also experience distress, uncertainty, and a sense of lack of control.

Management of symptoms to improve quality of life is the main reason to use palliative care. Without treatment for symptoms, patients may struggle with severe, uncomfortable, and painful side effects of the cancer and its treatments. Palliation can help patients physically but also give them better control over quality of life, which improves mental health.

Historically, palliative care was reserved for patients in the latter stages of cancer. However, literature supports introduction of palliative care at the time of diagnosis, especially for those cancers that tend to be aggressive with shorter survival trends. Palliative care can work in conjunction with the medical and surgical oncology teams to provide patient centered care. Mesothelioma is a particularly painful cancer, though, and palliation early on in the disease can be beneficial too.

Studies have shown that cancer patients with early access to palliative care enjoyed better quality of life and improved survival times.

Patients in need of palliative care will generally work with a specialist. Some centers have dedicated palliative care teams. They have specialty training in palliative care and can create a strategy with the patient and their family. If a dedicated team is not available, the medical care team can certainly have a more palliative approach and work to provide support that best fits an individuals goals.

The actual medical procedures are provided by physicians. The palliative care specialist will also reach out to other caregivers to help implement the plan: pain specialists, holistic care providers, pharmacists, physical therapists, psychologists, spiritual leaders, and others.

Palliative treatments do not have to wait until a patient is in hospice car. Hospice may be in a medical facility or at home, but is care that is provided to patients at the end of their lives. Palliative care does not require enrollment into hospice.

Palliative care becomes especially important in hospice, where it provides relief, comfort, and the best possible quality of life for the time a patient has left.

Patients living with pleural mesothelioma experience a number of difficult symptoms, including pain, a relentless cough, and difficulty breathing. Several treatments, including surgery, chemotherapy, and radiation therapy can be used for relief and palliation:

Many of the same strategies used for pleural mesothelioma palliation can be applied to the peritoneal patient. Paracentesis is the term for removing fluid from the abdomen. Standard chemotherapy may provide some benefits, but radiation is not generally used for peritoneal mesothelioma.

The buildup of fluid in the abdomen, know as ascites, can be particularly uncomfortable for peritoneal patients. Specialists who provide HIPEC, a debulking surgery followed by heated chemotherapy, may offer this service for palliation. It is generally used as a treatment to slow or cure the cancer, but studies have also found it can improve quality of life as a palliative treatment.

Managing this rare type of mesothelioma is especially challenging because it is so close to the heart. A percardiocentisis a surgical procedure that can be used to drain fluid from around the heart, which relieves pressure and pain. Chemotherapy may also help relieve symptoms, but radiation is not effective with pericardial mesothelioma.

A surgical procedure known as a pericardiectomy may help relieve symptoms specific to this type of mesothelioma. It involves removing part or all of the pericardium around the heart. This may help relieve pressure on the heart, which is both uncomfortable and dangerous.

For any type of mesothelioma, pain is a major symptom and focus of palliative treatment. The medical treatments used for each type can help relieve pain but are often not adequate. Medications and other management strategy can help reduce pain or make it more tolerable:

While most complementary and alternative (CAM) practices are unproven to help treat cancer, they can help manage symptoms and play an important role in palliative care.

For example, a study from MD Anderson Cancer Center included 375 cancer patients and found that acupuncture relieved several symptoms: fatigue, hot flashes, numbness, nausea, and dry mouth.

CAM may also include aromatherapy, massage therapy, herbal supplements, and other strategies. Patients may have a CAM specialist on their treatment or palliative care team. Some CAM practices may help some patients feel better or not work for others. Most are safe to try, though.

Palliative treatments are essential for helping mesothelioma patients enjoy a better quality of life. This is a devastating disease that is most often terminal but also very painful physically. Palliative care can provide psychological and spiritual assistance and medical treatments to relieve symptoms.

Sources

Follow this link:

Palliative Treatment for Mesothelioma - Mesothelioma.net Blog